ConductScience.org, home

Trial · NCT04985604

Results by group84

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Overall Response Rate (ORR) by the InvestigatorMelanoma Cohort50.095% Confidence Interval 15.7 to 84.3Percentage of participants
Overall Response Rate (ORR) by the InvestigatorTissue Agnostic Cohort40.095% Confidence Interval 16.3 to 67.7Percentage of participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Melanoma CohortAny TEAE8Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Tissue Agnostic CohortAny TEAE15Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Melanoma CohortTEAEs Related to Study Drug8Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Tissue Agnostic CohortTEAEs Related to Study Drug13Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Melanoma CohortAny serious TEAE2Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Tissue Agnostic CohortAny serious TEAE8Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Melanoma CohortSerious TEAEs Related to Study Drug0Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Tissue Agnostic CohortSerious TEAEs Related to Study Drug1Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Melanoma CohortTEAEs with Severity Grade 3 or Higher5Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Tissue Agnostic CohortTEAEs with Severity Grade 3 or Higher8Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Melanoma CohortTEAEs Related to Study Drug with Severity Grade 3 or Higher2Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Tissue Agnostic CohortTEAEs Related to Study Drug with Severity Grade 3 or Higher3Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Melanoma CohortTEAEs Leading to Death0Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Tissue Agnostic CohortTEAEs Leading to Death0Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Melanoma CohortTEAEs Related to Study Drug Leading to Death0Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Tissue Agnostic CohortTEAEs Related to Study Drug Leading to Death0Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Melanoma CohortTEAEs Leading to Study Drug Discontinuation1Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)Tissue Agnostic CohortTEAEs Leading to Study Drug Discontinuation0Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04985604/results